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Background: Familial hypercholesterolaemia (FH) is a common Mendelian condition which, untreated, results
in premature coronary heart disease. An estimated 88% of FH cases are undiagnosed in the UK. We previously
validated a method for FH mutation detection in a lipid clinic population using next generation sequencing (NGS),
but this did not address the challenge of identifying index cases in primary care where most undiagnosed patients
receive healthcare. Here, we evaluate the targeted use of NGS as a potential route to diagnosis of FH in a primary
care population subset selected for hypercholesterolaemia.
Methods: We used microfluidics-based PCR amplification coupled with NGS and multiplex ligation-dependent
probe amplification (MLPA) to detect mutations in LDLR, APOB and PCSK9 in three phenotypic groups within the
Generation Scotland: Scottish Family Health Study including 193 individuals with high total cholesterol, 232 with
moderately high total cholesterol despite cholesterol-lowering therapy, and 192 normocholesterolaemic controls.
Results: Pathogenic mutations were found in 2.1% of hypercholesterolaemic individuals, in 2.2% of subjects on
cholesterol-lowering therapy and in 42% of their available first-degree relatives. In addition, variants of uncertain
clinical significance (VUCS) were detected in 1.4% of the hypercholesterolaemic and cholesterol-lowering therapy
groups. No pathogenic variants or VUCS were detected in controls.
Conclusions: We demonstrated that population-based genetic testing using these protocols is able to deliver
definitive molecular diagnoses of FH in individuals with high cholesterol or on cholesterol-lowering therapy. The
lower cost and labour associated with NGS-based testing may increase the attractiveness of a population-based
approach to FH detection compared to genetic testing with conventional sequencing. This could provide one
route to increasing the present low percentage of FH cases with a genetic diagnosis.
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Familial hypercholesterolaemia (FH, OMIM no.143890)
is a common autosomal dominant disorder characterised
by raised serum cholesterol, increased arterial deposition
of low density lipoprotein (LDL)-cholesterol and high
risk of premature coronary heart disease (CHD). Clinical
diagnosis is based on the presence of raised total or LDL-
cholesterol, tendon xanthomata, corneal arcus, family
history and the presence of FH-causing mutations in
the LDLR, PCSK9 or APOB genes [1]. The prevalence
of FH is estimated to be between 1/200 and 1/500 [2,3],
and while most of the excess risk of premature CHD
can be averted by cholesterol lowering drugs, currently
only 12-25% of cases in the UK, and <1% in the USA
are believed to have a molecular diagnosis [3,4].
Genetic testing and family cascade screening has been
proposed as the most cost-effective strategy for detecting
cases of FH [3,5], and for distinguishing monogenic FH
from sporadic or polygenic hypercholesterolaemia [6].
This strategy was adopted in the 2008 UK guidelines from
the National Institute for Health and Clinical Excellence
(NICE) [7]. However, implementation of these guidelines
in England has been limited due to poor availability, low
throughput and high costs of traditional genetic testing,
fragmented service delivery and lack of investment in
identification of index cases.
We previously demonstrated that next generation se-
quencing (NGS) is suitable for FH mutation detection
in patients attending lipid clinics, with similar sensitivity
and specificity to conventional capillary sequencing [8].
Moreover, NGS mutation detection is suited to high-
throughput testing of large numbers of samples, which is
not so readily achievable with standard capillary sequen-
cing platforms. Since the majority of undiagnosed FH
patients receive their healthcare outside lipid clinics, we
sought to assess the feasibility of targeted sequence-based
genetic testing for FH in a primary care-based population
subset selected for hypercholesterolaemia.
Methods
DNA samples
The Generation Scotland: Scottish Family Health Study
(GS:SFHS) is a repository of anonymised biological sam-
ples and accompanying clinical, biochemical and family
data from 23,960 Scottish residents [9]. The ability to
recruit at least one first-degree relative was a condition
for participation in the GS:SFHS, and therefore around
two thirds of those taking part are consenting adult
relatives of recruits and volunteers.
We selected a subset of GS:SFHS subjects for genetic
analysis using criteria designed to enrich the test popula-
tion for individuals likely to have FH, based on previously
reported population total cholesterol data in FH [10,11],
and using additional age and body mass index (BMI)thresholds to reduce inclusion of age- and obesity-related
cases of hyperlipidaemia (Figure 1). Triglyceride levels
were not measured in the Generation Scotland cohort and
therefore data for LDL-cholesterol were not available.
Subjects were consequently selected for study on the
basis of total cholesterol data. In total, 617 unrelated
subjects were obtained from the GS:SFHS and passed
quality control (QC; see below) for NGS and MLPA:
193 individuals with raised total cholesterol (designated
high cholesterol group), 232 individuals with moderately
high total cholesterol despite cholesterol-lowering therapy
(cholesterol-therapy group) and 192 normocholesterolae-
mic controls. The control group, also from the GS:SFHS
study, were selected to be closest to the population spe-
cific mean total cholesterol level, and were age, sex and
BMI matched to the high cholesterol group (Table 1 and
Figure 1). Total cholesterol cut-off thresholds for each
study group are defined in Figure 1. Of all study subjects,
84.1% were White Scottish, 8.6% other Caucasians, 2.0%
mixed race and other ethnic groups, and 5.3% unknown
ethnicity.
Demographic data of the study population is summarised
in Table 1. The median age of the cholesterol-therapy
group was higher than the high cholesterol and control
groups reflecting higher cholesterol-lowering drug pre-
scription rates in older subjects in this primary care
population. 40% of these individuals were known to be
taking statins, while the remainder were on unspecified
cholesterol lowering medication. Study subjects in the
cholesterol-therapy group were selected from those
with total cholesterol ≥5.5 mmol/l, these being unlikely
to have achieved lipid-lowering therapy targets for FH
[12]. DNA samples for available first-degree relatives of
index cases who tested positive for FH mutations were
obtained from the GS:SFHS repository, and were tested by
Sanger sequencing for mutations detected in their respect-
ive proband relatives. Ethical approval for the GS:SFHS
study was obtained from the Tayside Committee on Med-
ical Research Ethics (on behalf of the National Health
Service). All patients provided informed consent for the
use of their data and samples for medical research.
Mutation detection
The full LDLR coding sequence, all four exons known to
harbour FH mutations in PCSK9, and the known muta-
tion hot spot in APOB were amplified using the 48.48
Access Array (Fluidigm, San Francisco, USA) and pooled
samples sequenced on a MiSeq sequencer (Illumina, San
Diego, USA) as described [8]. Due to the very low likeli-
hood of detecting mutations that could be definitively
shown to be pathogenic in the remainder of the PCSK9
and APOB genes, it was considered that inclusion of
these regions in the assay would not be informative and
these regions were therefore not included in the assay.
Figure 1 Selection criteria for GS:SFHS high cholesterol, cholesterol-therapy and control groups. Groups of subjects selected for the study
are shaded. The number of unrelated participants studied in each category of total cholesterol level, age and body mass index is shown. Numbers in
parentheses denote the total number of participants in the entire GS:SFHS cohort within each study group. TC: Total cholesterol.
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tions outside coding regions or splice sites, intronic regions
outside splice sites were not covered in this assay.
DNA sequences were considered to have passed QC
if >90% of all nucleotides were covered at ≥15x and >98%
of LDLR coding regions were covered at ≥15×. Mean
coverage for all DNA samples passing QC across all
amplicons was 2023× with a mean of 95.2% of bases cov-
ered at least 15×. Although this level of coverage falls below
recent recommendations for clinical grade sequencing [13],
our group established high sensitivity (98%) and specificity
(100%) for this NGS-assay at comparable levels of coverage
in a lipid clinic population [8]. Recent advances in MiSeq
sequencing protocols and further assay optimisation would,
however, allow further development that could lead to
levels of coverage that meet present recommendations.Table 1 Characteristics of Generation Scotland groups studied
Group Age Sex distribution
High cholesterol (n = 193) 44 (21–88) 41/59
Control (n = 192) 45 (21–84) 42/58
Cholesterol-therapy (n = 232) 60 (30–88) 43/57
Median data are given for age, BMI and total cholesterol. Ranges are shown in bracThe presence of large insertions/deletions was detected
using the MLPA (Multiplex Ligation-dependent Probe
Amplification) LDLR-P062 kit (MRC-Holland, Amsterdam,
The Netherlands) following the manufacturer’s protocol
including recommendations for QC.
Variant analysis
DNA sequences were mapped to the human GRCh37
reference assembly and variant calls generated and anno-
tated as described [8]. Variants with minor allele frequency
reported at greater than 1% in Ensembl [14], and intronic
variants outside exon-intron boundaries were considered
non-pathogenic and were excluded from further analysis.
Remaining variants were compared to an FH locus-specific
database [14,15], HGMD professional [16], and annotated
in silico using Variant Effect Predictor [14] and Mutation%M: %F BMI Total cholesterol (mmol/l)
26.9 (18.7-47.4) 8.1 (7.0-12.0)
26.4 (14.2-44.6) 5.2 (5.0-5.3)
28.1 (18.1-56.6) 5.9 (5.5-9.5)
kets.
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in mutation databases were classified as pathogenic. All
remaining known variants were classified as variants of
uncertain clinical significance (VUCS) unless published
data indicated that these variants are likely benign. Novel
missense variants were also classified as VUCS. Novel
sequence changes outside coding regions and essential
splice sites, and synonymous coding changes were con-
sidered likely benign. As only 5’ and 3’ ends of introns
were represented in our NGS-assay, intronic variants
outside splice sites were not evaluated. All rare variants
were verified by conventional Sanger sequencing and
the single detected duplication was confirmed by PCR.
Results
Mutation detection
FH-causing mutations were detected in 4 out of 193
(2.1%) subjects in the high-cholesterol group and in 5
out of 232 (2.2%) subjects in the cholesterol-therapy
group (Table 2). All nine mutations have been previously
reported as pathogenic in FH patients [15,16]. No FH-
causing mutations were detected in the 192 subjects in
the normocholesterolaemic control group.
Five VUCS were detected in six subjects from the high-
cholesterol and cholesterol-therapy groups (Table 2), but
none in normocholesterolaemic controls. Three of the five
detected variants have been previously reported in FH
patients but their pathogenicity is unclear [8,15]. The
two missense changes, p.Glu92Lys substitution in PCSK9
and p.Val765Gly in LDLR, have not been reported before
and further segregation and functional studies will be
needed to clarify the pathogenicity of these variants.
Two additional rare non-synonymous coding sequence
variants in LDLR were identified in three study subjects,
but their previously reported presence in normocholes-
terolaemic individuals has led to their classification as
benign variants [18]. The p.Arg744Gln variant was found in
two cholesterol-treated subjects not known to be related,
whose total cholesterol measurements on treatment were
7.7 mmol/l and 9.5 mmol/l. The p.Ala50Ser was found in
one control subject (total cholesterol 5.3 mmol/l).
Cascade testing
DNA was available for cascade testing in relatives of six
of the index cases identified here as having pathogenic
mutations. From a total of twelve available first-degree
relatives, five molecular diagnoses of FH were made: one
from the two relatives of index case 4, three from the
five relatives of index case 8, and one from the single
relative of index case 9 (Table 2). In all cases mutations
identified in relatives were the same as that of the associ-
ated index case. Single first-degree relatives of index cases
2 and 5, and two first-degree relatives from index case 7,
were mutation negative. Cholesterol data was available forthree of the five new molecular diagnoses: two of these
subjects had relatively high cholesterol levels despite being
on cholesterol-lowering therapy (5.0 mmol/l and
5.5 mmol/l); the third subject was untreated, with a
cholesterol level of 7.7 mmol/l.
Discussion
Sequence-based detection of index cases and family
cascade testing offer a possible route to diagnosis of FH
in primary care, but this approach has not been evaluated
to date. In this study we have used our recently validated
NGS-based assay [8] and MLPA to detect FH-causing
mutations in a primary care-based population in subjects
who, based on readily available clinical data, were con-
sidered to have an increased risk of FH compared to
the general population. In the sample of GS:SFHS patients
tested, we found pathogenic, FH-causing mutations in
2.1% of unrelated high risk individuals and none in nor-
mocholesterolaemic controls. A further five FH cases were
identified through cascade testing of first degree relatives
of index cases by testing for the identified mutation found
in each index case. We also detected VUCS in 1.4% of the
high-cholesterol and cholesterol-therapy groups, but none
in normocholesterolaemic controls. Further functional
and segregation studies will be needed to clarify pathogen-
icity of these variants. The interpretation of VUCS in NGS
projects remains a challenge, although given the present
rapid increase in available, clinically relevant sequencing
data and the expansion of disease-specific databases,
we anticipate that the clinical interpretation of variants
currently classified as VUCS is likely to become easier
in the coming months and years.
The GS:SFHS is a primary care-based study of subjects
aged 35–65 at recruitment, and their consenting adult
relatives, phenotyped for a range of biochemical and
morphometric parameters including body mass index,
total cholesterol and history of medical prescriptions [9].
These clinical details were used to ascertain subjects
who would be enriched for FH-causing mutations, but
in most cases were not sufficient to apply formal clinical
diagnostic criteria for FH (Simon Broome or Dutch Lipid
Clinic) [19,20]. No data was collected on clinical pheno-
types such as tendon xanthomata, and while some family
history information was collected, it did not include suffi-
cient detail (for example age at onset of cardiovascular
disease) to apply Simon Broome or Dutch Lipid Clinic
criteria. A family history of hypercholesterolaemia could
only be established for those with relatives who had been
recruited to the study. In subjects from the cholesterol-
therapy group, pre-treatment cholesterol measurements
were not available. Although preventing clinical diagnostic
criteria from being applied, this level of information is
analogous to the available data in a previous UK study of
FH which used casenote review without genetic testing in
Table 2 Pathogenic FH mutations and variants of uncertain clinical significance (VUCS) found in Generation Scotland subjects
No. Age Sex Total cholesterol (mmol/l) Group Gene Nucleotide change Protein change PolyPhen2 prediction SIFT prediction Mutation taster n
Pathogenic mutations
1 51 F 12.0 High cholesterol APOB c.10580G > A p.Arg3527Gln Probably damaging Deleterious Polymorphism 1
2 44 F 8.9 LDLR c.693C > G p.Cys231Trp Probably damaging Deleterious Disease causing 1
3 36 M 7.0 LDLR c.268G > A p.Asp90Asn Probably damaging Deleterious Disease causing 1
4 61 F 8.3 LDLR c.718G > A p.Glu240Lys Possibly damaging Deleterious Disease causing 1
5 56 M 5.9 Cholesterol-therapy APOB c.10580G > A p.Arg3527Gln Probably damaging Deleterious Polymorphism 1
6 57 M 5.7 LDLR c.326G > A p.Cys109Tyr Probably damaging Deleterious Disease causing 1
7 50 M 5.9 LDLR c.1133A > C p.Gln378Pro Probably damaging Deleterious Polymorphism 1
8 71 F 5.5 LDLR c.232C > T p.Arg78Cys Probably damaging Tolerated Disease causing 1
9 60 F 6.2 LDLR c.1586-?_1845 + ?dup Not applicable Not applicable Not applicable 1
(Exon 11 and 12 duplication)
VUCS
10 32 F 7.7 High cholesterol PCSK9 c.274G > Aa p.Glu92Lys Benign Tolerated Polymorphism 1
11 31 M 8.7 LDLR c.-121 T > C Not applicable Not applicable Not applicable Polymorphism 1
12 54 F 8.2 LDLR c.1816G > T p.Ala606Ser Possibly damaging Tolerated Disease causing 1
13 63 M 5.5 Cholesterol-therapy LDLR c.2294 T > Ga p.Val765Gly Benign Tolerated Polymorphism 2b
14 61 M 7.0
15 36 M 6.0 LDLR c.2479G > A p.Val827Ile Probably damaging Deleterious Disease causing 1
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in entry criteria between primary care and Lipid Clinic
populations, and illustrates the importance of careful
selection criteria for this approach to molecular diagnosis
in primary care. Of interest, however, was that within our
high cholesterol group, a subset of 50 individuals who
were aged 40 or under had total cholesterol 7–7.4 mmol/l
and therefore do not meet Simon Broome criteria for
FH. One of this group was found to have an FH causing
mutation (see below).
The mutation detection rate reported here is consider-
ably lower than in Lipid Clinic populations tested ac-
cording to defined clinical criteria [8,21], but is higher
than the detection rate in an unselected population study
in Copenhagen, in which only 20% of those diagnosed
clinically as having probable or definite FH (0.73% of the
study population) were found by genotyping to have a
common FH mutation [22]. The low FH detection rate in
comparison to Lipid Clinic populations is most likely a
consequence of the limited clinical data such as the
absence of information on tendon xanthomata and LDL-
cholesterol, as well as the probable inclusion of individuals
with polygenic and lifestyle related hypercholesterolaemia
which is reportedly of high prevalence in the Scottish
compared to the English population [23] which may also
have affected our ability to enrich this group for genetic
effects. The availability of data on LDL-cholesterol and
presence or absence of tendon xanthomata in future study
populations, as well as genetic testing in populations with
a lower background frequency of cardiovascular disease
are likely to allow greater enrichment for patients with FH
in those selected for testing, with a corresponding higher
FH detection rate.
Treatment targets are more stringent in FH compared
to sporadic hypercholesterolaemia owing to the greater
vascular risk caused by lifelong high cholesterol levels [12],
and therefore it is notable that the number of molecular
diagnoses we made in the cholesterol-therapy group was
similar to that of the high cholesterol group. Although
individuals in the cholesterol-therapy group are receiving
lipid-lowering medication, their relatively high cholesterol
levels (5.5 – 6.2 mmol/l) suggest suboptimal treatment,
which could most likely be addressed by more aggressive
lipid-lowering therapy, ideally in a lipid clinic. Molecular
diagnosis in these individuals would also permit cascade
testing of their relatives. Consistent with the experience
from the Dutch cascade screening programme [3,24],
these data illustrate the advantages of identifying FH in
primary care by genetic testing in order to distinguish FH
patients definitively from those with other types of hyper-
cholesterolaemia. Making use of NGS-based techniques to
identify FH cases in primary care also provides a feasible
alternative to reliance on lipid clinics in countries such
as England and the USA where genetic testing for FH isnot generally carried out and overall diagnostic rates
remain low.
The selection criteria we employed here may not detect
all mutation positive FH cases in primary care. For example,
Index Case 3 (Table 1; TC = 7.0 mmol/l) was on the lower
cholesterol threshold for inclusion in our study. In addition,
since only 13% of patients in the GS:SFHS on cholesterol-
lowering therapy had total cholesterol ≥5.5 mmol/l, further
testing of subjects on cholesterol-lowering therapies but
with cholesterol <5.5 mmol/l would be likely to make
further molecular diagnoses of FH and these would be a
source of additional cases through family cascade testing.
Conclusions
To our knowledge, this is the first study of FH based on
DNA sequencing in a primary care population. Previous
studies to detect FH in primary care populations have
been based on clinical criteria alone [10,25], or genotyping
for common mutations [22]. We have evaluated the tar-
geted use of high-throughput NGS-based methods for
detection of FH cases in primary care, and demonstrated
that population-based genetic testing using these proto-
cols is able to deliver definitive molecular diagnoses of
FH in high-risk individuals. Because detection of FH
cases in primary care would require testing of much larger
numbers of subjects than detection of cases in secondary
care, the lower cost and labour associated with NGS-
based testing [8,26,27] could increase the attractiveness of
a population-based approach to FH detection compared
to genetic testing with conventional sequencing. Coupled
with genetic testing in lipid clinics, selective NGS-based
population screening with family cascade testing could
therefore be one route to increasing the present low
percentage of FH cases with a genetic diagnosis. Detailed
studies should now be undertaken to establish the feasibil-
ity and cost-effectiveness of this approach.
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